Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$1.53 - $2.89 $42,163 - $79,642
-27,558 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.67 - $4.68 $19,966 - $34,997
-7,478 Reduced 21.34%
27,558 $74,000
Q4 2021

Feb 15, 2022

SELL
$3.87 - $7.39 $164,761 - $314,621
-42,574 Reduced 54.86%
35,036 $152,000
Q3 2021

Nov 15, 2021

SELL
$4.32 - $6.43 $51,779 - $77,069
-11,986 Reduced 13.38%
77,610 $395,000
Q2 2021

Aug 16, 2021

SELL
$6.33 - $9.91 $20,952 - $32,802
-3,310 Reduced 3.56%
89,596 $567,000
Q1 2021

May 18, 2021

BUY
$6.6 - $9.0 $163,713 - $223,245
24,805 Added 36.42%
92,906 $718,000
Q3 2020

Nov 17, 2020

BUY
$6.55 - $8.83 $615 - $830
94 Added 0.14%
68,101 $453,000
Q1 2020

May 13, 2020

SELL
$3.61 - $8.6 $7,783 - $18,541
-2,156 Reduced 3.07%
68,007 $522,000
Q3 2019

Nov 15, 2019

BUY
$7.38 - $12.25 $6,184 - $10,265
838 Added 1.21%
70,163 $518,000
Q2 2019

Aug 14, 2019

BUY
$9.35 - $11.41 $6,339 - $7,735
678 Added 0.99%
69,325 $778,000
Q1 2019

May 09, 2019

SELL
$9.5 - $19.16 $3,296 - $6,648
-347 Reduced 0.5%
68,647 $738,000
Q4 2018

Feb 13, 2019

BUY
$12.69 - $18.61 $11,433 - $16,767
901 Added 1.32%
68,994 $1.04 Million
Q3 2018

Nov 14, 2018

BUY
$18.04 - $26.41 $163,731 - $239,697
9,076 Added 15.38%
68,093 $1.26 Million
Q2 2018

Aug 14, 2018

BUY
$21.38 - $29.68 $315,846 - $438,462
14,773 Added 33.39%
59,017 $1.35 Million
Q1 2018

May 15, 2018

SELL
$21.76 - $34.22 $33,749 - $53,075
-1,551 Reduced 3.39%
44,244 $1.26 Million
Q4 2017

Feb 14, 2018

SELL
$19.0 - $23.09 $12,369 - $15,031
-651 Reduced 1.4%
45,795 $967,000
Q3 2017

Nov 13, 2017

BUY
$13.53 - $18.17 $628,414 - $843,923
46,446
46,446 $844,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $69.9M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.